Hanmi Pharm
한미약품 · 128940
Health Care Pharmaceuticals · KOSPI
Market cap US$4.7B (₩6.5T)
Overview
Hanmi Pharm makes prescription medicines for conditions such as high blood pressure, high cholesterol, acid reflux, and erectile dysfunction, and supplies them to patients and healthcare providers in South Korea and internationally.
Its subsidiary Hanmi Jeongmil Hwahak produces active pharmaceutical ingredients, the raw chemical compounds used to manufacture finished drugs, and exports them to over forty countries, including to multinational pharmaceutical companies. Listed on the KOSPI, South Korea's main stock exchange, the company operates across three distinct segments: domestic pharmaceuticals, active ingredients, and an overseas pharmaceutical business based in China.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$1.1B
- FY2024US$1.1B
- FY2025US$1.1B
Operating profit
- FY2023US$159.9M
- FY2024US$156.7M
- FY2025US$186.8M
Net income
- FY2023US$119.8M
- FY2024US$101.8M
- FY2025US$135.6M
Key ratios (FY2025)
Why it matters
Its China-based subsidiary, 북경한미약품유한공사, was established by Hanmi Pharm and operates as an independent pharmaceutical company handling its own research, manufacturing, and sales.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?